RELAPSE
Clinical trials for RELAPSE explained in plain language.
Never miss a new study
Get alerted when new RELAPSE trials appear
Sign up with your email to follow new studies for RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental antibody drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study looks at how well the drug glofitamab works in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are tracking how many patients achieve a complete response after receiving glofitamab through a compassionate use p…
Matched conditions: RELAPSE
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New program aims to help people with addiction stay clean
Disease control CompletedThis study tested a culturally adapted relapse prevention program (RPM-08) for people with substance use disorder in Pakistan. 70 male participants in residential rehab either received the program plus usual care or usual care alone. The program consisted of eight weekly group se…
Matched conditions: RELAPSE
Phase: NA • Sponsor: Universiti Sains Malaysia • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Immune cell therapy shows promise for tough lymphoma cases
Disease control CompletedThis early-stage trial tested a personalized cell therapy called CD19 CAR T cells in 20 adults with relapsed or refractory B-cell lymphoma. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells, and infusing them back. T…
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New pill shows promise for tough blood cancers in early trial
Disease control CompletedThis early-phase study tested an experimental oral drug called LP-108, given alone or with another drug (azacitidine), in 32 adults with blood cancers (MDS, CMML, or AML) that returned or didn't respond to prior therapy. The main goals were to find the safest dose and understand …
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC